Novo Nordisk Foundation

• estradiol

  Estrogen receptor agonist for hormone replacement

  Approved, Small molecule, ESR2, Inflammation, atrophic vaginitis, hypogonadism

• liraglutide

  GLP-1 receptor agonist that enhances glucose-dependent insulin secretion.

  Approved, Peptide, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, cardiovascular disease, cardiovascular events

• oestradiol

  Estrogen receptor agonist for hormone replacement

  Approved, Small molecule, ESR2, Inflammation, atrophic vaginitis, hypogonadism

10 more assets

• Novo Nordisk

  13 assets, 493 trials

• Prevalence of Silent Atherosclerosis across Adult Life

  The New England journal of medicine, 31 Aug 2026

• Epigenetic ageing is accelerated in drug-resistant epilepsy and dynamically modulated during ketogenic diet therapy

  EBioMedicine, 22 Aug 2026

• Effects of Supervised Vigorous Exercise on Tissue-Specific Insulin Resistance in South Asian and Nordic Women with Previous Gestational Diabetes

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Targeting Endogenous Retroviruses as a Novel Immunometabolic Therapy: HERV-K Activation in Human Tissues and Proof-of-Concept Rescue in Diabetic Mice

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026

• Assessing Fairness of QPrediction Models Using UK Biobank Data

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• Diabetogenic Processes for Increased Insulin Resistance with Concomitant Hyperinsulinemia Are Associated with Increased Colorectal Cancer Risk

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

  Lancet (London, England), 12 Mar 2015